Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

Share Price Information for Directa Plus (DCTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.60 (8.696%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.50
DCTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Co-Mask Anti-Viral (COVID-19) Properties Confirmed

13 Aug 2020 07:00

RNS Number : 9772V
Directa Plus PLC
13 August 2020
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN .

 

13 August 2020

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Strong Anti-Viral (COVID-19) Properties Confirmed for Co-Mask™

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that its G+® graphene enhanced facemask, Co-mask™, has been confirmed as having strong anti-viral properties by a team at the Department of Neuroscience, Catholic University of Rome, operating in conjunction with the Gemelli Hospital in Rome.

 

The team, under Professor Massimiliano Papi, tested G+® enhanced fabrics with SARS-CoV-2, the strain of coronavirus that causes the respiratory illness responsible for the ongoing COVID-19 pandemic. The preliminary results show that the G+® graphene can improve textile properties and significantly reduce the measured incidence of SARS-CoV-2 when the virus is deposited or filtered through functionalised cotton or a non-woven fabric (polyurethane). A scientific paper containing the full details of the trial and the results is underway and is expected to be published shortly.

 

The Company's Co-mask™ range of G+® enhanced masks is designed to be suitable for use by commuters, in the workplace, and for sport and exercise. The masks offer an optimum balance between breathability and filtration efficiency and thanks to the use of G+® are a natural and environmentally sustainable solution. The masks are washable at least 50 times, providing material cost benefits and, in addition to being strongly anti-bacterial, they have now been confirmed as having anti-SARS-CoV-2 properties. The Company's range was launched in June and is available for retail sale at a dedicated website: https://graphene-plus.com/

 

Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "I would like to congratulate Professor Papi and his team on the first research project to test G+® graphene enhanced fabrics for their anti-viral qualities and, importantly, their ability to significantly reduce occurrence of SARS-CoV-2. I am also pleased that the team has verified the anti-bacterial properties of graphene enhanced fabrics, which are essential for the prolonged use of masks.

 

"These preliminary results confirm that the application of our technology can significantly enhance facemask efficacy and can help to reduce the spreading of SARS-CoV-2. Our G+® graphene solutions are non-toxic and environmentally sustainable, overcoming the health and other problems associated with current ion-metal or halogen treatments. The Company is now in early stage discussions with possible commercial partners for this application."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Marco Ferrari, CFO

 

 

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald

Pete Lynch

 

 

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Mark Taylor

 

 

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson, Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBLGDILSBDGGD
Date   Source Headline
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar
31st Jan 20247:00 amRNSContract win with FORD Otosan
20th Dec 20237:00 amRNSAcquisition of groundbreaking technology
15th Dec 202311:44 amRNSExpansion of collaboration with Miguel Caballero
10th Nov 20237:00 amRNSChange of Nominated Adviser
27th Sep 20237:00 amRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic collaboration with The SPECTRUM Group
8th Sep 20237:00 amRNSNotice of Interim Results
7th Sep 20237:00 amRNSSignificant contract secured with LIBERTY Galati
19th Jul 20237:00 amRNSProject tender awarded
29th Jun 20237:00 amRNSDirecta Plus receives two new Italian patents
22nd Jun 20237:00 amRNSNew concept for produced water decontamination
15th Jun 20235:40 pmRNSResult of AGM
8th Jun 20237:00 amRNSNew product launch
19th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
10th May 20237:00 amRNSFinal Results
9th May 20237:00 amRNSNew contract with customer Alfredo Grassi
27th Apr 20237:00 amRNSNotice of Results Presentations
20th Mar 20237:00 amRNSNew Patent Granted
27th Feb 20237:00 amRNSTrading Update and Notice of Results
21st Dec 20227:00 amRNSNew significant contract with Pigmentsolution
5th Dec 20222:05 pmRNSSecond Price Monitoring Extn
5th Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSTrading Update
29th Nov 20227:00 amRNSGrant Award
21st Nov 20227:00 amRNSDirectorate Change
28th Oct 20227:00 amRNSFirst Commercial Contract in Latin America
21st Oct 20227:00 amRNSFirst Major Commercial Contract for Gipave
17th Oct 20227:00 amRNSBoar Changes
17th Oct 20227:00 amRNSBoard Changes
29th Sep 202211:05 amRNSSecond Price Monitoring Extn
29th Sep 202211:00 amRNSPrice Monitoring Extension
29th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSTrading Statement
30th Aug 20227:00 amRNSUS Patent Notice
4th Aug 20227:00 amRNSPartnership Extension and US Patent Award
19th Jul 20227:00 amRNSAgreement with REDA Energy for Grafysorber
5th Jul 20227:00 amRNSSupply Agreement
22nd Jun 20227:00 amRNSGrant of Italian Filtration Patent
17th Jun 20223:40 pmRNSResult of AGM
17th Jun 20227:00 amRNSAGM Statement
19th May 20227:00 amRNSPosting of Annual Report and Notice of AGM
5th May 20227:00 amRNSFinal Results
22nd Apr 20227:00 amRNSPartnership to Develop Automotive Fabrics
4th Apr 20227:00 amRNSUS EPA Authorises Grafysorber for Use in US
7th Mar 20227:00 amRNSOxfordshire Starts Second Trial of GiPave

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.